Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Lowered by Lockheed Martin Investment Management Co.

Lockheed Martin Investment Management Co. lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 30.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,210 shares of the biopharmaceutical company’s stock after selling 990 shares during the period. Lockheed Martin Investment Management Co.’s holdings in Regeneron Pharmaceuticals were worth $1,676,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Kestra Investment Management LLC increased its position in shares of Regeneron Pharmaceuticals by 2.4% in the third quarter. Kestra Investment Management LLC now owns 675 shares of the biopharmaceutical company’s stock valued at $512,000 after buying an additional 16 shares in the last quarter. AlphaCore Capital LLC raised its stake in shares of Regeneron Pharmaceuticals by 133.5% during the 3rd quarter. AlphaCore Capital LLC now owns 1,602 shares of the biopharmaceutical company’s stock worth $1,215,000 after buying an additional 916 shares during the period. Leuthold Group LLC raised its stake in shares of Regeneron Pharmaceuticals by 11.2% during the 3rd quarter. Leuthold Group LLC now owns 10,303 shares of the biopharmaceutical company’s stock worth $7,812,000 after buying an additional 1,038 shares during the period. Fulcrum Asset Management LLP purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $519,000. Finally, StoneRidge PMG Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $610,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Morgan Stanley lifted their price target on shares of Regeneron Pharmaceuticals from $779.00 to $855.00 and gave the company an “equal weight” rating in a research note on Monday, November 2nd. Jefferies Financial Group upped their price objective on shares of Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Truist Financial upped their price objective on shares of Regeneron Pharmaceuticals from $780.00 to $982.00 and gave the stock a “buy” rating in a research report on Monday, November 2nd. Bank of America increased their price objective on shares of Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the company a “buy” rating in a report on Monday, November 2nd. Finally, Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $898.97.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 4,466 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $965.49, for a total transaction of $4,311,878.34. Following the sale, the executive vice president owned 38,906 shares of the company’s stock, valued at $37,563,353.94. The trade was a 10.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Marion Mccourt sold 1,215 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the sale, the executive vice president directly owned 13,134 shares of the company’s stock, valued at $11,163,900. The trade was a 8.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 27,028 shares of company stock worth $25,025,950 in the last quarter. 6.97% of the stock is owned by insiders.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $919.96 on Tuesday. The stock has a 50 day moving average of $806.90 and a two-hundred day moving average of $743.66. Regeneron Pharmaceuticals, Inc. has a 12 month low of $591.52 and a 12 month high of $991.73. The firm has a market cap of $94.72 billion, a P/E ratio of 20.31, a price-to-earnings-growth ratio of 1.38 and a beta of 0.10. The company has a current ratio of 3.35, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating the consensus estimate of $16.51 by $3.56. The business had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business’s quarterly revenue was up 36.3% compared to the same quarter last year. During the same quarter last year, the business posted $11.83 earnings per share. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be paid a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions.

The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Founded in 1988, Regeneron is headquartered in Tarrytown, New York.